ABSTRACT
Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).
Subject(s)
Anti-HIV Agents , HIV Infections , Anti-HIV Agents/therapeutic use , HIV/genetics , HIV Infections/drug therapy , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Oxazines , Piperazines , Pyridones , RNA/therapeutic useABSTRACT
: In the ADVANCE study of first-line treatment, there were 48 participants with HIV RNA at least 50âcopies/ml in the week 48 window who had subsequent follow-up data available with no change in randomized treatment. More participants achieved virological re-suppression in the TAF/FTC+DTG and TDF/FTC+DTG arms (26/34, 76%) than on TDF/FTC/EFV (6/14â=â43%; Pâ=â0.0421). It is unclear whether participants with HIV RNA at least 50âcopies/ml at week 48 should be termed 'virological failures' on integrase inhibitor-based treatment.
